Our Lady of the Lake Cancer Institute welcomed Harry Sequeira, MD, to the Heme-Malignancy and Cell Therapy Program. He is a board-certified internal medicine physician and specializes in cellular therapy, leukemia, and myelodysplastic disorders.
Our Lady of the Lake Cancer Institute has also recently become a site for a Phase I clinical trial with Poseida for allogeneic CAR-T therapy, making the Institute the first in state.
Sequeira is a graduate of the Hematology-Oncology fellowship at Cook County Health, where he served as chief fellow. He previously completed his internal medicine residency at Saint Barnabas Hospital in New York, serving as chief medical resident.
His academic and clinical trajectory has been complemented by robust research involvement. He was a registered investigator with the National Cancer Institute (NCI) during his final year of fellowship and has authored numerous peer-reviewed publications and abstracts presented at national conferences, including American Society of Clinical Oncology and The American College of Chest Physicians. His scholarly work spans hematologic malignancies, solid tumors and healthcare disparities, with a strong focus on clinical outcomes and health systems research.
.